Associate Professor Drew is head of the Molecular Metabolism and Ageing Laboratory at the Baker Heart & Diabetes Institute, Australia, where he also leads the Cardiometabolic Disease & Obesity Division. His other roles include Scientific leads of both the In Vivo CRISPR Validation Platform, and the Preclinical Phenotyping Platform at Baker. His research focuses on engaging cutting-edge technologies including systems genetics, CRISPR, lipid nanoparticle therapeutics and phenomics to identify novel diagnostics and therapeutic targets for diseases related to ageing, mitochondrial function and degeneration.